This standard specifies the requirements, test methods, marking, labeling, instructions for use, packaging, transportation and storage of lipoprotein-associated phospholipase A2 assay kit (chemiluminescence immunoassay).
The document provides a detailed explanation of the drafting process for a new industry standard concerning the Lipoprotein-associated Phospholipase A2 (Lp-PLA2) assay kit using chemiluminescence immunoassay. It outlines the task source from the National Medical Products Administration, the timeline of discussions held in 2023 involving experts from hospitals and regulatory bodies, and the formation of a working group to establish unified technical requirements.
The text justifies the need for this standard by noting the lack of existing national or international standards for Lp-PLA2 kits, which hinders the evaluation of product safety and efficacy. It details the performance indicators selected for the standard, such as appearance, traceability, limit of detection, accuracy, linearity, precision, and stability, based on market surveys and clinical requirements. The document also lists the relevant national and international standards referenced during the drafting process. This manual is written in Chinese.
It quantitatively determines lipoprotein-associated phospholipase A2 by chemiluminescence immunoassay.
The kit can use tube, magnetic particles, microbeads, and plastic beads as carriers.
It is also called platelet-activating factor acetylhydrolase (PAF-AH) and has a molecular weight of 45 kDa.
It is an independent risk factor for coronary heart disease and ischemic stroke.